Celecoxib induces apoptosis via a mitochondria-dependent pathway in the H22 mouse hepatoma cell line

Molecular Medicine Reports

Volumn 10, Issue 4, 2014, Pages 2093-2098

  Shao, Dan ^a   Kan, Mujie ^a   Qiao, Ping ^a   Pan, Yue ^a   Wang, Zheng ^a   Xiao, Xuanang ^a   Li, Jing ^a   Chen, Li ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Apoptosis; Celecoxib; Liver cancer; Mitochondria

Indexed keywords

APOPTOSIS INDUCING FACTOR; CASPASE 3; CASPASE 9; CELECOXIB; CYCLOOXYGENASE 2; CYTOCHROME C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN BAX; PROTEIN BCL 2; SULFORHODAMINE B; ANTINEOPLASTIC AGENT; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; FLOW CYTOMETRY; HEPATOCELLULAR CARCINOMA CELL LINE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; WESTERN BLOTTING; ANIMAL; DRUG EFFECTS; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; MITOCHONDRION; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS INDUCING FACTOR; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; CYTOCHROMES C; LIVER NEOPLASMS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZOLES; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 84923003228     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2461     Document Type: Article

References (31)

1. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576, 2007. (Pubitemid 46890874)
2. Grivennikov SI, Greten FR and Karin M: Immunity, inflammation, and cancer. Cell 140: 883-899, 2010.
3. Raoul JL, Sangro B, Forner A, et al: Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 37: 212-220, 2011.
4. Fort J: Celecoxib, a COX-2-specific inhibitor: the clinical data. Am J Orthop (Belle Mead NJ) 28 (3 Suppl): 13-18, 1999.
5. Chakraborti AK, Garg SK, Kumar R, et al: Progress in COX-2 inhibitors: a journey so far. Curr Med Chem 17: 1563-1593, 2010.
6. Xie SQ, Zhang YH, Li Q, et al: COX-2-independent induction of apoptosis by celecoxib and polyamine naphthalimide conjugate mediated by polyamine depression in colorectal cancer cell lines. Int J Colorectal Dis 27: 861-868, 2012.
7. Wang ZL, Fan ZQ, Jiang HD, et al: Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling. Carcinogenesis 34: 638-646, 2013.
8. Bocca C, Bozzo F, Bassignana A and Miglietta A: Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines. Mol Cell Biochem 350: 59-70, 2011.
9. Bastos-Pereira AL, Lugarini D, de Oliveira-Christoff A, et al: Celecoxib prevents tumor growth in an animal model by a COX-2 independent mechanism. Cancer Chemother Pharmacol 65: 267-276, 2010.
10. Wang AH, Tian XY, Yu JJ, et al: Celecoxib radiosensitizes the human cervical cancer HeLa cell line via a mechanism dependent on reduced cyclo-oxygenase-2 and vascular endothelial growth factor C expression. J Int Med Res 40: 56-66, 2012.
11. Jendrossek V: Targeting apoptosis pathways by Celecoxib in cancer. Cancer Lett 332: 313-324, 2013.
12. Bruix J and Sherman M; American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022, 2011.
13. Schattenberg JM, Schuchmann M and Galle PR: Cell death and hepatocarcinogenesis: Dysregulation of apoptosis signaling pathways. J Gastroenterol Hepatol 26 (Suppl 1): 213-219, 2011.
14. Tan TT and White E: Therapeutic targeting of death pathways in cancer: mechanisms for activating cell death in cancer cells. Adv Exp Med Biol 615: 81-104, 2008.
15. Fulda S and Debatin KM: Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25: 4798-4811, 2006. (Pubitemid 44187627)
16. Xu Z, Zhang M, Lv X, et al: The inhibitory effect of celecoxib on mouse hepatoma H22 cell line on the arachidonic acid metabolic pathway. Biochem Cell Biol 88: 603-609, 2010.
17. Dai ZJ, Ma XB, Kang HF et al: Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in vitro and in vivo. Cancer Cell Int 12: 53, 2012.
18. Maier TJ, Schilling K, Schmidt R, et al: Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 67: 1469-1478, 2004. (Pubitemid 38388209)
19. Cervello M, Bachvarov D, Cusimano A, et al: COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells. OMICS 15: 383-392, 2011.
20. Lin MT, Lee RC, Yang PC, et al: Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 276: 48997-49002, 2001.
21. Yan YX, Li WZ, Huang YQ, et al: The COX-2 inhibitor Celecoxib enhances the sensitivity of KB/VCR oral cancer cell lines to Vincristine by down-regulating P-glycoprotein expression and function. Prostaglandins Other Lipid Mediat 97: 29-35, 2012.
22. Grosch S, Maier TJ, Schiffmann S and Geisslinger G: Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 98: 736-747, 2006. (Pubitemid 43983297)
23. Pyrko P, Soriano N, Kardosh A, et al: Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. Mol Cancer 5: 19, 2006.
24. Rudner J, Elsaesser SJ, Müller AC, et al: Differential effects of anti-apoptotic Bcl-2 family members Mcl-1, Bcl-2, and Bcl-xL on celecoxib-induced apoptosis. Biochem Pharmacol 79: 10-20, 2010.
25. 2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. Biochem J 366: 831-837, 2002.
26. Rahman M, Selvarajan K, Hasan MR, et al: Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo. Neoplasia 14: 624-633, 2012.
27. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
28. Ricote M, Li AC, Willson TM, et al: The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391: 79-82, 1998. (Pubitemid 28079218)
29. Birnbaum Y, Long B, Qian J, et al: Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR-gamma- independent manner. Basic Res Cardiol 106: 431-446, 2011.
30. Lin Y, Bai L, Chen W and Xu S: The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets 14: 45-55, 2010.
31. Zhang M, Xu ZG, Shi Z, et al: Inhibitory effect of celecoxib in lung carcinoma by regulation of cyclooxygenase-2/cytosolic phospholipase A2 and peroxisome proliferator-activated receptor gamma. Mol Cell Biochem 355: 233-240, 2011.